Insights on the Pulmonary Arterial Hypertension (PAH) Drugs Global Market to 2027: Increasing Prevalence of Cardiovascular and Pulmonary Disorders Drives Growth
Global Pulmonary Arterial Hypertension (PAH) Drugs Market
Dublin, Feb. 03, 2023 (GLOBE NEWSWIRE) -- The "Pulmonary Arterial Hypertension (PAH) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
The global pulmonary arterial hypertension (PAH) drugs market size reached US$ 6.9 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 9.4 Billion by 2027, exhibiting a CAGR of 5.29% during 2021-2027.
Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Pulmonary arterial hypertension (PAH) refers to a life-threatening medical condition characterized by high blood pressure in the arteries that connect the heart to the lungs. It causes the artery walls to tighten and narrow down, thereby exerting additional pressure on the heart to pump blood and weakening the muscles.
In adverse cases, it can also compromise the heart's capacity to pump blood, thus eventually causing heart failure. PAH is characterized by shortness of breath, fatigue and swelling in ankles and legs. It is diagnosed through various tests, such as an echocardiogram, computer tomography (CT) scans, chest X-rays and ventilation-perfusion scans.
It is usually treated using various drugs, such as endothelin receptor antagonists (ERAs), vasodilators, calcium channel blockers (CCBs), anticoagulants, diuretics and cardiac glycosides. These drugs can be inhaled, injected or orally administered.
The increasing prevalence of cardiovascular and pulmonary disorders is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population that is more susceptible to such medical ailments is providing a boost to the market growth.
In line with this, changes in lifestyles, such as excessive alcohol consumption, a lack of physical activity, and unhealthy dietary patterns, have enhanced the risks of hypertension and high blood pressure.
This, along with the development of novel orphan drugs and technologically advanced devices for the treatment of PAH, is favoring the market growth. Other factors, including increasing awareness among the masses regarding the available treatment alternatives for PAH, and improving healthcare infrastructure across the globe, are expected to drive the market further.
The report has also analysed the competitive landscape of the market with some of the key players being Actelion Pharmaceuticals Ltd (Johnson & Johnson), Arena Pharmaceuticals Inc., AstraZeneca PLC, Bayer Aktiengesellschaft, Daiichi Sankyo Company Limited, Gilead Science Inc., GlaxoSmithKline PLC, Merck KGaA, Novartis International AG, Pfizer Inc. and United Therapeutics Corporation.
Key Questions Answered in This Report:
How has the global pulmonary arterial hypertension (PAH) drugs market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global pulmonary arterial hypertension (PAH) drugs market?
What are the key regional markets?
What is the breakup of the market based on the drug class?
What is the breakup of the market based on the route of administration?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global pulmonary arterial hypertension (PAH) drugs market and who are the key players?
What is the degree of competition in the industry?
No. of Pages
2021 - 2027
Estimated Market Value (USD) in 2021
Forecasted Market Value (USD) by 2027
Compound Annual Growth Rate
Key Topics Covered:
2 Scope and Methodology
3 Executive Summary
4.2 Key Industry Trends
5 Global Pulmonary Arterial Hypertension (PAH) Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Class
6.1 Endothelin Receptor Antagonists (ERAs)
6.1.1 Market Trends
6.1.2 Market Forecast
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Phosphodiesterase-5 (PDE-5) Inhibitors
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Soluble Guanylate Cyclase (sGC) Stimulators
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Calcium Channel Blockers (CCBs)
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Prostacyclin and Prostacyclin Analogs
6.6.1 Market Trends
6.6.2 Market Forecast
6.7.1 Market Trends
6.7.2 Market Forecast
7 Market Breakup by Route of Administration
7.1.1 Market Trends
7.1.2 Market Forecast
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Oral Administration
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by End User
8.1.1 Market Trends
8.1.2 Market Forecast
8.2.1 Market Trends
8.2.2 Market Forecast
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Region
10 SWOT Analysis
11 Value Chain Analysis
12 Porters Five Forces Analysis
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Actelion Pharmaceuticals Ltd (Johnson & Johnson)
184.108.40.206 Company Overview
220.127.116.11 Product Portfolio
14.3.2 Arena Pharmaceuticals Inc.
18.104.22.168 Company Overview
22.214.171.124 Product Portfolio
126.96.36.199 SWOT Analysis
14.3.3 AstraZeneca PLC
188.8.131.52 Company Overview
184.108.40.206 Product Portfolio
220.127.116.11 SWOT Analysis
14.3.4 Bayer Aktiengesellschaft
18.104.22.168 Company Overview
22.214.171.124 Product Portfolio
126.96.36.199 SWOT Analysis
14.3.5 Daiichi Sankyo Company Limited
188.8.131.52 Company Overview
184.108.40.206 Product Portfolio
220.127.116.11 SWOT Analysis
14.3.6 Gilead Science Inc.
18.104.22.168 Company Overview
22.214.171.124 Product Portfolio
126.96.36.199 SWOT Analysis
14.3.7 GlaxoSmithKline PLC
188.8.131.52 Company Overview
184.108.40.206 Product Portfolio
220.127.116.11 SWOT Analysis
14.3.8 Merck KGaA
18.104.22.168 Company Overview
22.214.171.124 Product Portfolio
126.96.36.199 SWOT Analysis
14.3.9 Novartis International AG
188.8.131.52 Company Overview
184.108.40.206 Product Portfolio
14.3.10 Pfizer Inc.
220.127.116.11 Company Overview
18.104.22.168 Product Portfolio
22.214.171.124 SWOT Analysis
14.3.11 United Therapeutics Corporation
126.96.36.199 Company Overview
188.8.131.52 Product Portfolio
184.108.40.206 SWOT Analysis
For more information about this report visit https://www.researchandmarkets.com/r/1yh585
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900